Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers -

Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers
Information type: Other primary research
Source: British Journal of Clinical Pharmacology
Specialities: Gastrointestinal disorders
Summary
A study on the effects of esomeprazole and vonoprazan on the pharmacokinetics of proguanil, a CYP2C19 substrate, in 7 healthy males concluded that both PPIs potentially inhibit CYP2C19 at clinical doses, therefore co-administration with CYP2C19 substrates is cautioned.
UKMi comment
Vonoprazan fumarate is a first-in-class, orally bioavailable potassium-competitive acid blocker. It was approved in the Japanese market in February 2015.
Related links: